The state of Illinois currently has 463 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717
Recruiting
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiatio... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Rush - Copley Medical Center, Aurora, Illinois +46 locations
Conditions: Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
NCT04333537
Recruiting
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy surgery is a procedure that removes a smaller number of lymph nodes from your neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard neck dissection, such as elective neck dissection, removes many of the lymph nod... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Northwestern University, Chicago, Illinois +3 locations
Conditions: Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
Register for Updates
Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
NCT05610826
Recruiting
Doctors and researchers leading this study hope to learn more about peptide receptor radionuclide therapy (PRRT) in combination with cytoreduction (surgically removing tumors). They hope to learn if combining PRRT in combination with cytoreduction would be more effective than cytoreduction alone. PRRT itself is approved by the U.S. Food and Drug Administration (FDA) for people with PanNETs however the combination with cytoreduction is considered experimental. Your participation in this research... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/26/2024
Locations: The University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Pancreatic Neuroendocrine Tumor, Pancreas Cancer
Register for Updates
Detecting HPV DNA in Anal and Cervical Cancers
NCT04857528
Recruiting
This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer. Doctors leading this study will use blood tests to find out if they can detect the HPV virus in the blood of study participants before, during, and after radiation treatment. They will also collect blood and archival tumor tissue (from a previous biopsy) to perform other tests in the future that could provide more info... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/26/2024
Locations: University of Illinois at Chicago, Chicago, Illinois +1 locations
Conditions: Cervical Cancer, Anal Cancer, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, Uterine Cervical Cancer
Register for Updates
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
NCT04541381
Recruiting
Doctors leading this study hope to find out if giving study participants' genetic information to cancer care providers will help personalize chemotherapy dosing decisions and decrease common chemotherapy side effects. Doctors leading the study will collect genetic information from study participants using pharmacogenomics/genotyping. Pharmacogenomics is the study of how the differences in our genes can affect our unique response to medications. This is a randomized study, which means that parti... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/26/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Gastrointestinal Cancer, Breast Cancer, Head and Neck Cancer, Dihydropyrimidine Dehydrogenase Deficiency, UGT1A1 Gene Mutation
Register for Updates
Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens
NCT04821141
Recruiting
Women at risk for development of breast cancer and experiencing vasomotor menopausal symptoms (hot flashes) will be randomized to bazedoxifene (BZA) plus conjugated estrogens (CE) for 6 months versus a wait list control. Two risk factors for development of breast cancer will be studied pre-study and after 6 months: fibroglandular volume (FGV) on mammogram as assessed by Volpara software and proliferation by Ki-67 immunocytochemistry in benign breast tissue acquired by random periareolar fine nee... Read More
Gender:
Female
Ages:
Between 45 years and 64 years
Trial Updated:
01/25/2024
Locations: Northwestern Medical Center, Chicago, Illinois
Conditions: Risk Reduction, Breast Cancer
Register for Updates
PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing
NCT03423264
Recruiting
Enrollment is only available to patients enrolled on the Optima II study (NCT03107182). The purpose of this trial is to compare rates of opioid use at completion of radiation for patients with Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 2 oral mucositis after receiving definitive nonoperative locoregional therapy with or without prophylactic gabapentin as part of best supportive care for locoregionally-advanced, HPV-related oropharyngeal cancer. Secondary purposes include com... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/25/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Oropharyngeal Cancer, HPV-Related Squamous Cell Carcinoma
Register for Updates
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
NCT06169371
Recruiting
This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of their treating providers
Gender:
All
Ages:
18 years and above
Trial Updated:
01/25/2024
Locations: University of Illinois, Chicago, Illinois
Conditions: Breast Cancer
Register for Updates
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
NCT05296512
Recruiting
This research study is being done to test the efficacy and safety of combining the study drugs pembrolizumab and lenvatinib in patients with clear cell ovarian cancer. The names of the study drugs involved in this study are: Lenvatinib Pembrolizumab
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/25/2024
Locations: University of Chicago Medicine, Chicago, Illinois
Conditions: Ovarian Clear Cell Carcinoma, Gynecologic Cancer
Register for Updates
Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
NCT06084338
Recruiting
This trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined with PSMA targeted radiopharmaceutical therapy and cessation of castration, and then followed by testosterone replacement, is an effective treatment for metastatic castration resistant prostate cancer. All patients will be treated with stereotactic ablative radiotherapy and PSMA targeted radiopharmaceutical th... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
01/23/2024
Locations: Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois
Conditions: Prostate Cancer
Register for Updates
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949
Recruiting
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2024
Locations: Northwest Oncology & Hematology, Rolling Meadows, Illinois
Conditions: Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Register for Updates
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
NCT06085742
Recruiting
This is a non-randomized, single arm phase 2 trial of oral CMC based on conversion of doses that would be delivered with conventional metronomic CMF chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/10/2024
Locations: University of Illinois, Chicago, Illinois
Conditions: Breast Cancer
Register for Updates